Global interventional cardiology devices market is projected to witness a CAGR of 8.37% during the forecast period 2024–2031, growing from USD 16.22 billion in 2023 to USD 30.86 billion in 2031. The interventional cardiology devices market is thriving due to factors like a growing prevalence of cardiovascular disorders, technological advancements in cardiology devices, an increasing number of regulatory approvals, a growing geriatric population, rising awareness about cardiac conditions and treatment options, and increasing healthcare expenditure. Government initiatives and contributions from non-profit medical organizations to reduce the cardiac disease burden and strengthen the healthcare infrastructure are some other factors positively impacting the interventional cardiology devices market growth.

However, the dominance of first-line alternative treatment options pushes back the demand for interventional cardiology devices. The high cost of surgical procedures and instruments used for cardiac surgery makes it the terminal choice for middle and lower-class patients. Alongside, risks associated with cardiac surgeries and interventional devices hinder the growth of this market.

In November 2023, Argon Medical Devices, a trusted provider of device solutions for interventional radiology, vascular surgery, interventional cardiology, and oncology, introduced the Kodiak Dual Port Coaxial Introducer Kit. This innovative kit enables precise and streamlined introduction of diagnostic and therapeutic devices into the vasculature, ensuring optimum results for patients.

Technological Advancements in Cardiology Devices
Technological advancements in interventional cardiology devices have been significant in recent years. These advancements include the use of robotic technologies, miniature surgical robots controlled by surgeons, navigational sensors for precision, and wireless technologies with biosensors. Additionally, advancements in robotic percutaneous coronary intervention (PCI) technology, including improvements in wire manipulation, guide catheter control, and IVUS imaging, have been observed. Furthermore, wireless technologies and biosensors hold promise for interventional cardiology, as they can be used for various applications such as monitoring and diagnosis. These advancements are enhancing the precision, safety, and effectiveness of interventional cardiology procedures, ultimately benefiting interventional cardiology devices. Key players are designing products with enhanced technologies to cater to the market needs.

In September 2023, Canon Medical launched the Alphenix Sky 12 HD interventional system with the new high-definition (Hi-Def) detector. The Alphenix Sky 12 HD features a 12"×12" Hi-Def detector to improve visualization for interventional procedures, including pediatric cases, in cardiology, neurology, oncology, and radiology.

Get Full Report here: https://www.marketsandata.com/industry-reports/interventional-cardiology-devices-market

Growing Prevalence of Cardiovascular Diseases
Cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. The prevalence of cardiovascular diseases is expected to increase substantially due to factors such as population growth and aging. The rise in cardiovascular disease cases is attributed to a lack of translation of existing knowledge about cardiovascular diseases and risk factors into practice. The burden of cardiovascular diseases is particularly heavy on low- and middle-income countries, where they contribute to poverty and place a significant economic strain. Unhealthy diet, physical inactivity, tobacco use, and alcohol consumption are among the most important behavioral risk factors for cardiovascular diseases. The demand for interventional cardiology devices is expected to increase significantly with the growing prevalence of cardiovascular diseases.

For instance, according to the World Heart Report 2023 published by the World Heart Federation, cardiovascular diseases have been the leading cause of death worldwide for many years. In 2021, more than 20 million people died from a cardiovascular condition, which accounted for about one-third of all global deaths. This figure is significantly higher than the 12.1 million cardiovascular disease deaths recorded in 1990. Ischemic heart disease is now the leading cause of premature death in 146 countries for men and 98 countries for women.

Dominance of Stents Segment
The stents segment is anticipated to be the leading segment in the interventional cardiology devices market. Stents are commonly used in interventional cardiology to treat coronary artery disease. They are expandable tubular metallic devices introduced into clogged coronary arteries, a procedure known as percutaneous coronary intervention (PCI) or coronary stenting. The most widely used stents are drug-eluting stents (DES), which have significantly reduced the incidence of restenosis in native stable coronary arteries. Stents have been shown to reduce angina and improve survival in patients with coronary artery disease. Innovative stent products from market players have significantly developed the market.

In October 2023, Medinol announced the United States Food and Drug Administration (FDA) approval for its EluNIR-PERL drug-eluting stent (DES), which is meant for the treatment of coronary artery disease. EluNIR-PERL has four radiopaque markers, two at each end, and a hybrid polymer-metal radiopaque catheter tip. These unique features allow excellent visualization during PCI procedures, whether navigating through complex anatomies or placing the stent precisely.

Ambulatory Surgical Centers to be the Fastest Growing End-user Segment
Cardiology procedures are increasingly being performed in ambulatory surgery centers (ASCs) due to various factors such as improved patient experiences, strong reimbursement rates, and cost savings. These procedures include the placement of pacemakers, loop recorders, AICD, diagnostic and interventional coronary procedures, peripheral vascular interventions, right and left heart catheterizations, coronary interventions, and defibrillator and pacemaker implants. The Centers for Medicare and Medicaid Services (CMS) support this shift to ASCs by adding cardiology procedures to the ASC-covered procedure list. This has led to a faster growth rate for ambulatory surgical centers. For instance, as per an article published by HMP Global in July 2023, around 2% of major cardiovascular procedures are being performed in ambulatory surgical centers and the traction is steadily rising.

North America to be the Dominating Region
North America is anticipated to be the leading region in interventional cardiology devices. The region has a high prevalence of cardiovascular diseases, leading to a significant demand for cardiology devices. Additionally, North America has a high adoption rate of minimally invasive procedures and a strong presence of top manufacturers in the interventional cardiology device market. The rising healthcare expenditure and high disposable incomes in North America also contribute to the dominance of the region in the interventional cardiology devices market. Alongside, prominent players in the interventional cardiology device market, such as Medtronic, Boston Scientific Corporation, and Abbott, have a strong presence in North America, further contributing to its dominance.

As per the American Heart Association, by 2035, almost 45% of the United States population is expected to experience heart disease due to unhealthy factors such as high obesity rates, smoking, and poor lifestyle choices. These factors may increase the risk of heart attacks and other related health issues.

Future Market Scenario (2024–2031F)
In recent years, notable regulatory emphasis has been helpful for novel marketed products. Several reforms have been made to speed up the approval process of interventional cardiology devices. The FDA has been granting several regulatory approvals for interventional cardiology devices. The classification of interventional cardiovascular implant simulation software devices has been updated to class II (special controls). Most class III devices require FDA approval of a PMA before they can be legally marketed. The classification of cardiovascular devices intended for human use that are in commercial distribution is outlined in 21 CFR Part 870. The number of cardiac device approvals for children seems to be growing, with most approvals being granted through the humanitarian device exemption (HDE) pathway.

In November 2023, Medtronic plc received approval from the United States Food and Drug Administration (FDA) for its Symplicity Spyral renal denervation (RDN) system, which is also known as the Symplicity blood pressure procedure. This system has been approved for use in treating hypertension. As a result of the approval, Medtronic will start the commercialization of the product right away. The device is mainly meant to reduce hypertension through relaxing nerves connected to the kidneys and reducing its activity.

Interventional cardiology devices represent a crucial aspect of modern cardiovascular care, offering minimally invasive solutions for the diagnosis and treatment of various heart conditions. This market segment has witnessed significant growth in recent years, driven by advancements in technology, increasing prevalence of cardiovascular diseases (CVDs), and rising demand for less invasive procedures. This research-based content aims to provide an overview of the interventional cardiology devices market, exploring key trends, drivers, challenges, and future prospects.

Download Free Sample Report: https://www.marketsandata.com/industry-reports/interventional-cardiology-devices-market/sample-request

Market Dynamics:
Rising Burden of Cardiovascular Diseases: Cardiovascular diseases, including coronary artery disease, heart failure, and arrhythmias, remain a leading cause of mortality worldwide. The growing prevalence of risk factors such as hypertension, diabetes, and obesity has contributed to the increased incidence of CVDs, driving the demand for interventional cardiology devices.

Technological Advancements: The interventional cardiology field continues to benefit from ongoing technological innovations. Advancements in imaging modalities, catheter-based technologies, stent designs, and drug-eluting technologies have enhanced procedural success rates, reduced complications, and improved patient outcomes.

Shift towards Minimally Invasive Procedures: Patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional open surgeries due to benefits such as shorter recovery times, reduced hospital stays, and lower morbidity rates. Interventional cardiology devices enable clinicians to perform complex interventions, such as coronary angioplasty and transcatheter valve replacement, through small incisions or catheter-based approaches.

Growing Geriatric Population: The aging population, particularly in developed regions, is more susceptible to cardiovascular diseases. As the elderly population continues to grow, there is a corresponding increase in the demand for interventional cardiology procedures and devices to manage age-related cardiovascular conditions.

Segmentation:
The interventional cardiology devices market can be segmented based on product type, application, end-user, and geography:
Product Type: Coronary Stents, Catheters, Guidewires, Balloon Inflation Devices, Intravascular Imaging Systems, Structural Heart Devices, and Others.

Application: Coronary Intervention, Peripheral Vascular Intervention, Structural Heart Intervention, and Others.
End-User: Hospitals, Cardiac Centers, Ambulatory Surgical Centers, and Others.
Geography: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Key Players:
Some of the prominent players in the interventional cardiology devices market include:
Abbott Laboratories
Medtronic plc
Boston Scientific Corporation
Terumo Corporation
Johnson & Johnson
B. Braun Melsungen AG
C. R. Bard, Inc. (acquired by BD)
Cardinal Health, Inc.
Edwards Lifesciences Corporation
Cook Medical Incorporated

Challenges and Opportunities:
Despite the promising growth prospects, the interventional cardiology devices market faces challenges such as pricing pressures, stringent regulatory requirements, and the risk of complications associated with device implantation. Moreover, the COVID-19 pandemic has temporarily impacted procedural volumes and device sales due to the postponement of elective procedures and resource reallocation.

However, ongoing research and development efforts aimed at developing innovative devices, expanding indications for existing products, and penetrating emerging markets offer significant growth opportunities for market players. Additionally, collaborations between industry stakeholders, healthcare providers, and regulatory agencies can facilitate the development and adoption of novel interventional cardiology technologies.

Conclusion:
The interventional cardiology devices market is poised for continued growth, driven by technological advancements, increasing disease burden, and shifting healthcare preferences towards minimally invasive procedures. Market players must remain vigilant to evolving trends and invest in research and development to address unmet clinical needs and capitalize on emerging opportunities, ultimately contributing to improved patient outcomes and enhanced cardiovascular care.

Contact
Mr. Vivek Gupta
5741 Cleveland street, 
Suite 120, VA beach, VA, USA 23462
Tel: +1 (757) 343–3258
Email: [email protected]
Website: https://www.marketsandata.com